EP1836304A2 - An der angiogeneseregulierung beteiligte gene, pharmazeutische zubereitungen damit und deren verwendung - Google Patents

An der angiogeneseregulierung beteiligte gene, pharmazeutische zubereitungen damit und deren verwendung

Info

Publication number
EP1836304A2
EP1836304A2 EP06709059A EP06709059A EP1836304A2 EP 1836304 A2 EP1836304 A2 EP 1836304A2 EP 06709059 A EP06709059 A EP 06709059A EP 06709059 A EP06709059 A EP 06709059A EP 1836304 A2 EP1836304 A2 EP 1836304A2
Authority
EP
European Patent Office
Prior art keywords
sequence
identified
seq
under
sequence listing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06709059A
Other languages
English (en)
French (fr)
Inventor
Sylvie Colin
Salman Al-Mahmood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gene Signal International SA
Original Assignee
GENE SIGNAL INT SA
Gene Signal International SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENE SIGNAL INT SA, Gene Signal International SA filed Critical GENE SIGNAL INT SA
Publication of EP1836304A2 publication Critical patent/EP1836304A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention belongs to the field of pharmaceutical compositions useful for the treatment of pathologies resulting from deregulation of the mechanism of angiogenesis.
  • the present invention also relates to the polypeptide sequences of the factors encoded by said genes which find their application in the clinical study of the process of angiogenesis, the prognosis, the diagnosis and the treatment of pathologies related to this process as well as in the implementation of pharmacological, pharmacogenomic or pharmacosignalitic tests.
  • Angiogenesis is a fundamental process by which new blood vessels are formed. This process is essential in many normal physiological phenomena such as reproduction, development or healing. In these normal biological phenomena, angiogenesis is under strict control, i.e. it is triggered for a short period, a few days, and then completely inhibited.
  • Arthritis for example, is a condition caused by cartilage damage by invasive neovessels. In diabetic retinopathy, invasion of the retina by neovessels leads to the blindness of patients; the neovascularization of the ocular apparatus presents the major cause of blindness and this neovascularization dominates about twenty diseases of the eye.
  • tumor growth and metastasis are directly related to neovascularization and are dependent on angiogenesis.
  • the tumor stimulates the growth of neovessels for its growth itself.
  • these neovessels present tumor escape routes to join the bloodstream and cause metastases in distant sites such as the liver, lung or bone.
  • angiogenesis may present an important therapeutic basis. Indeed, the promotion of angiogenesis in damaged areas can lead to the formation of lateral and alternative blood vessels to damaged vessels thus providing blood and therefore oxygen and other nutritive and biological factors necessary for survival. affected tissues.
  • neovessels by endothelial cells involves the migration, growth, and differentiation of endothelial cells.
  • the regulation of these biological phenomena is directly related to gene expression.
  • angiogenesis an ever increasing number of studies show that the regulation of angiogenesis is done through an equilibrium between factors acting directly on the endothelial cell. These factors can be stimulating, on the one hand, such as, among others, VEGF, FGFs, IL-8, HGF / SF, PDGF. They can also be inhibiting, as, among others, I 1 IL-10, IL-12, gro- ⁇ and ⁇ , platelet factor 4, angiostatin, the human chondrocyte - derived inhibitor, thrombospondin, the leukemia inhibitory factor.
  • control of angiogenesis therefore represents a strategic axis, at the same time of fundamental research, in order to improve our understanding of the numerous pathological phenomena related to the angiogenesis, but also a base for the development of the new therapies intended to treat the angiogenesis. pathologies related to angiogenesis.
  • a method for identifying novel genes involved in the regulation of angiogenesis has been developed. It has been the subject of a French patent application published under No. FR 2798674 and of an international patent application PCT published under No. WO 01/218312. This method has the particularity of faithfully translating the intimate mechanism regulating angiogenesis by taking into account all the extracellular factors described as agents. angiogenesis regulators, i.e. angiogenic factors, angiostatic factors, as well as the various components of the extracellular matrix. This methodology consists of implementing these different extracellular factors through four well-defined experimental conditions.
  • the endothelial cells are cultured on a component and / or a well-defined mixture of several components of the extracellular matrix and placed under the four experimental conditions, namely: a control condition where the endothelial cells are not stimulated; an angiogenic condition where the endothelial cells are stimulated by one or more angiogenic factors; a condition for inhibiting angiogenesis wherein the endothelial cells are stimulated by one or more angiogenic factors and brought into the presence of one or more angiostatic factors; and another control condition where the endothelial cells are stimulated by one or more angiostatic factors.
  • angiogenesis including positive regulators and negative regulators.
  • the method described above allows the systematic screening of all the angiogenic and angiostatic factors as well as the different components of the extracellular matrix in order to highlight and identify genes encoding cellular constituents involved in the regulation of angiogenesis.
  • gene expression can be analyzed throughout the kinetics of neovessel formation by endothelial cells, this approach provides an in vitro methodology for linking gene expression to biological functional parameters of the endothelial cells. angiogenesis.
  • the invention relates to a nucleic acid molecule, characterized in that it comprises or consists of i) one of the nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 1, 2 , 4, 5, 9 to 11, 13, 17 to 19, 27 to 29 and 34 or its complement or a fragment of said sequences or an equivalent sequence; ii) an antisense sequence of one of the sequences of i), identified in the sequence listing provided in the annex under the numbers SEQ ID 62, 63, 65, 67, 69, 73, 74, 81, 82 and 85 or its complementary or a fragment of said sequences or an equivalent sequence; (iii) the antisense sequence identified in the sequence listing provided in the Annex under the number SEQ ID No. 86 or its complement or a fragment of said sequence or an equivalent sequence.
  • nucleotide sequences having one or more structural modifications, minor (s), not modifying their function should be considered as sequences equivalent to the sequences described above (see (s) the deletion, mutation or addition of bases, the identity of which is at least 90% with the nucleotide sequences identified as SEQ ID Nos. 1 to 34 in the attached sequence listing.
  • fragment is intended to mean a sequence of the 1Orner type, preferably of the 15-mer type and particularly preferably of the 2Orner type.
  • the invention relates to a polypeptide or fragment of said polypeptide, characterized in that it is encoded by one of the nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 1, 4, 5. , 13, 17, 18, 19 and 29.
  • said polypeptide comprises or consists of one of the polypeptide sequences identified in the sequence listing provided in the annex under the numbers SEQ ID No. 35,
  • the subject of the invention is an expression vector, characterized in that it comprises: i) a nucleic acid molecule as described previously; ii) a nucleic acid molecule characterized in that it comprises or consists of a) one of the nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID No.
  • said vector is chosen from the group of vectors GS-VI to GS-V23, identified by their sequence, bearing the numbers SEQ ID No. 87 to SEQ ID No. 109 in the attached sequence listing.
  • Said vectors can be constructed by any method known to those skilled in the art.
  • constructs are useful on the one hand for preparing therapeutic compositions for the treatment, by cell therapy, of angiogenic disorders and other on the other hand to verify the efficacy of a treatment of an angiogenic disorder in a mammal, in particular in a human being, or else to verify the functionality of the genes possibly involved in the mechanism of angiogenesis, in said mammal.
  • the invention relates to an antibody characterized in that it has an affinity for one of the polypeptide sequences encoded by one of the nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 1 to 34, or a fragment of said sequences, particularly coded by one of the nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 1, 4, 5, 13, 17, 18, 19 and 29 or a fragment thereof.
  • sequences or having an affinity for a polypeptide comprising or consisting of one of the polypeptide sequences identified in the sequence listing provided in the appendix as SEQ ID NO : 35 to 61, or a fragment thereof, particularly for a polypeptide comprising or consisting of in one of the polypeptide sequences identified in the sequence listing provided in the annex under the numbers SEQ ID No. 35, 37, 38 , 43, 47, 48, 49 or 57 or a fragment of said sequences.
  • Said antibodies can be obtained by any method of immunization in vivo or in vitro, of an animal, in particular a vertebrate and preferably a mammal with any of the polypeptide sequences according to the invention, or the one of their fragments preserving the immunogenicity of the total protein.
  • the antibodies may be polyclonal or monoclonal antibodies. (Kohler G. and Milstein C. Nature 1975 Aug 7; 256 (5517): 495-7.)
  • the invention relates to a genetically modified cell, characterized in that it over-expresses or under-expresses at least one gene involved in the angiogenesis chosen from the genes identified in the sequence listing. appended under the numbers SEQ ID No. 1 to SEQ ID No. 34, particularly the genes identified in the attached sequence listing under the numbers SEQ ID No. 1, 2, 4, 5, 9 to 11, 13, 17 to 19, 27 to 29 and 34.
  • the genetically modified cells may be constructed by any method known to those skilled in the art. In particular, they can be constructed by the method described in the patent application WO 03/074073 and which comprises:
  • step (b) culturing the cells obtained in step (a) in the presence of said antibiotic
  • the invention relates to the drug use of a nucleic acid molecule, a polypeptide, an expression vector, an antibody, or a genetically modified cell as previously described.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising as active agent at least one substance selected from: i) a nucleic acid molecule characterized in that it comprises or that it corresponds to a) one of the nucleotide sequences identified in the sequence listing provided appended under the numbers SEQ ID No. 1 to 34 or its complement or a fragment of said sequences or an equivalent sequence; b) an antisense sequence of one of the sequences of a), identified in the sequence listing provided as SEQ ID Nos. 64, 66, 67, 68, 70 to 72, 75 to 81 and 84, or its complementary or a fragment of said sequences or an equivalent sequence; (c) the antisense sequence identified in the sequence list provided in the Annex under the number
  • SEQ ID No. 86 or its complementary or a fragment of said sequence or an equivalent sequence.
  • a polypeptide characterized in that it is encoded by one of the nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 1 to 34 or that it comprises or consists of a polypeptide identified in the list sequence provided in the annex under the numbers SEQ
  • an expression vector characterized in that it comprises a nucleic acid molecule according to i) of the present claim; iv) an antibody characterized in that it has an affinity for one of the polypeptide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID Nos. 35 to 61 or for one of the sequences encoded by the nucleic acid sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID NO : 2, 9-11, 27, 28 and 34; v) a genetically modified cell characterized in that it over-expresses or under-expresses at least one gene chosen from those identified in the attached sequence listing under the numbers SEQ ID No. l to 34.
  • the pharmaceutical composition according to the invention may be intended for the diagnosis, prognosis and / or treatment of pathologies linked to I 1 angiogenesis.
  • the pharmaceutical composition may be intended for the treatment of pathologies related to angiogenesis chosen from: cancers, particularly through vascularization and / or proliferation of tumors, retinopathies, rheumatoid arthritis, Crohn 's disease, atherosclerosis, hyperstimulation of the ovary, psoriasis, endometrium associated with neovascularization, restenosis due to balloon angioplasty, tissue superproduction due to cicatrization , peripheral vascular disease, hypertension, vascular inflammation, Raynaud 's disease and phenomena, aneurysm, arterial restenosis, thrombophlebitis, lymphagyte, lymphodema, scarring and tissue repair, ischemia , angina, myocardial infarction, chronic heart disease, heart failure such as insufficiency congestive heart failure, age - related macular degeneration and osteoporosis.
  • angiogenesis chosen from: cancers, particularly through vascularization and / or proliferation of tumor
  • the invention relates to the use in the preparation of a pharmaceutical composition for inhibiting angiogenesis, characterized in that it comprises an active agent angiogenesis inhibitor selected from: i. a nucleic acid molecule characterized in that it comprises or that it corresponds to a. a nucleotide sequence identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 4 or 5 or a fragment of said sequence or an equivalent sequence; b. an antisense sequence of the nucleotide sequences identified in the sequence listing provided in the appendix under the number SEQ
  • an expression vector characterized in that it comprises a nucleic acid molecule according to i) of the present claim; iv. an antibody characterized in that it has an affinity for one of the polypeptide sequences identified in the sequence listing provided in the annex under the numbers SEQ ID No. 37 or 38 or a fragment of said polypeptides; v. a genetically modified cell characterized in that it overexpresses at least the gene identified in the attached sequence listing under the number SEQ ID No. 4 or 5 or that it sub-expresses at least one gene selected from those identified in the attached sequence list under the numbers SEQ ID No. 1 to 3 and 6 to 34.
  • the subject of the invention is the use in the preparation of a pharmaceutical composition intended to activate angiogenesis, characterized in that it comprises an activating active agent for angiogenesis chosen from: i) a nucleic acid molecule characterized in that it comprises or that it corresponds to a) one of the nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 1 to 3 or 6 to 34 or a fragment of said sequence or an equivalent sequence; b) the antisense sequence of one of the nucleotide sequences identified in the sequence listing provided in the annex under the number SEQ ID No. 4 or 5, sequence identified in the sequence listing provided in the appendix under the number SEQ ID No.
  • an activating active agent for angiogenesis chosen from: i) a nucleic acid molecule characterized in that it comprises or that it corresponds to a) one of the nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 1 to 3 or 6 to 34 or
  • polypeptide 65 or a fragment of said sequence or an equivalent sequence; ii) at least one polypeptide characterized in that it is encoded by one of the nucleotide sequences identified in the sequence listing provided in the appendix under the number SEQ ID No. 1 to 3 or 6 to 34 or that it comprises or consists of one of the polypeptides identified in the sequence listing provided in the appendix under the numbers SEQ ID No.
  • an expression vector characterized in that it comprises a nucleic acid molecule according to i) of the present claim; iv) an antibody characterized in that it has an affinity for the polypeptide sequence identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 35, 36, 39 to 61 or a fragment of said polypeptides; v) a genetically modified cell characterized in that it overexpresses at least one gene chosen from those identified in the attached sequence listing under the numbers SEQ ID No. 1 to 3 and 6 to 34 or that it sub- expresses a gene or sub-expresses at least the gene identified in the attached sequence listing under the number SEQ ID No. 4 or 5.
  • nucleic acid sequence in the form of DNA or RNA
  • nucleotide sequence chosen from the sequences identified by the numbers SEQ ID No. 1 to SEQ ID No. 34 in the sequence listing in the appendix, or complementary to such a sequence, preferably at least 15 seas.
  • the subject of the invention is the sequences having an identity of at least 85%, preferably 95% and particularly preferably 100% with a sequence chosen from the sequences identified under the numbers SEQ ID No. 62 to SEQ ID No. 86 in the attached sequence listing.
  • the invention relates to RNAi (RNA interference) and more specifically to a siRNA (small interfering RNA) comprising or consisting of a double - stranded nucleotide sequence in the form of RNA, of at least 10 mers, complementary to a corresponding mRNA. at one of nucleotide sequences identified as SEQ ID NO: 1 to SEQ ID NO: 34.
  • the subject of the invention is the use of such an siRNA of at least 10 mers, preferably at least 15 mers comprising or consisting of an RNA complementary to one of the nucleotide sequences identified under the numbers SEQ ID No. : 1 to SEQ ID No: 34 in the attached sequence listing for the preparation of a medicament for the treatment of pathological conditions related to angiogenesis.
  • the present invention also relates to a method for diagnosing an angiogenic pathology in a mammal, in particular in a human being, of detecting in the cells of said mammal the overexpression or the under-expression of one or more nucleotide sequences identified by the numbers SEQ ID No. 1 to SEQ ID No. 34 in the attached sequence listing.
  • Such a diagnostic method comprises the following steps: the detection of the expression of one or more of said nucleotide sequences SEQ ID No. 1 to SEQ ID No. 34, by a cell population of a mammal,
  • the present invention also relates to a method for diagnosis and prognosis of an angiogenic pathology in a mammal, in particular in a human being, of detecting in the cells of said mammal the overexpression or the under-expression of one or more identified polypeptide sequences. by the numbers SEQ ID No. : 35 to SEQ ID NO. : 61 in the sequence list in Annex .
  • said method comprises the following steps: a) the detection of the expression of one or more of said polypeptide sequences SEQ ID No. : 35 to SEQ ID
  • the detection of the expression of the sequences is carried out after putting the endothelial cells in the presence of a biological fluid from a patient.
  • the present invention also relates to a method for verifying the therapeutic efficacy of an angiogenic treatment in a mammal, in particular in a human being, characterized in that it comprises the identification
  • Such a method for verifying the therapeutic efficacy comprises the following steps: the detection of the expression by an isolated cell population of a mammal to which a therapeutic composition for treating an angiogenic disorder is administered, of at least one of the nucleotide sequences identified in the list sequences provided in the annex under the number SEQ ID N 0 1 to SEQ ID N 0 34; detecting the expression of said nucleotide sequence by a reference cell population whose angiogenic state is known, the identification of a possible difference in the level of expression of said sequence by the two cell populations.
  • the verification method is carried out on a cell population of a mammal in vivo, ex-vivo, or on an isolated cell population of said mammal in vitro.
  • the detection of the expression of the sequences is carried out after putting the cells, particularly the endothelial cells, in the presence of a biological fluid resulting from a patient.
  • the present invention also relates to a method for screening compounds useful for the angiogenic treatment of a mammal, in particular a human being.
  • such a screening method comprises the following steps: a) the detection of expression by an isolated cell population of a mammal placed in the presence of a compound likely to have a therapeutic effect on an angiogenic disorder, at least one of the nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID N 0 1 to SEQ ID No. 34, b) the detection of the expression of the same nucleotide sequence by a reference cell population whose angiogenic state is known, c) the identification of any differences in the level of expression of the same nucleotide sequence (s) by the two cell populations.
  • such a screening method also comprises the following steps: the detection of the expression of one or more of said polypeptide sequences identified by the numbers SEQ ID No. : 35 to SEQ ID No. 61 in the attached sequence listing by a cell population placed in the presence of a compound likely to have a therapeutic effect on an angiogenic disorder,
  • the detection of the expression of the sequences is carried out after putting the cells, particularly the endothelial cells, in the presence of a biological fluid originating from a patient. .
  • cancers particularly through the vascularization and / or proliferation of tumors, retinopathies, rheumatoid arthritis, Crohn 's disease, atherosclerosis, hyperstimulation of the ovary, psoriasis, endometrium associated with neovascularization, restenosis due to angioplasty of the balloon, tissue superproduction due to scarring, peripheral vascular disease , hypertension, vascular inflammation, Raynaud 's disease and phenomena, aneurysm, arterial restenosis, thrombophlebitis, lymphagyte, lymphodema, scarring and tissue repair, ischemia, angina, myocardial infarction, chronic heart disease, heart failure such as congestive heart failure, age - related macular degeneration and osteoporosis.
  • the subject of the invention is also a device comprising a support comprising one or more probes specific for one or more nucleotide sequences identified under the numbers SEQ ID No: 1 to SEQ ID No: 34 in the attached sequence listing for the setting implementation of the screening method of the invention, particularly one or more nucleotide sequences identified in the sequence listing provided in the appendix under the numbers SEQ ID No. 1, 4, 5, 13, 17, 18, 19 and 29, or its complement or a fragment of said sequences.
  • probe is understood to mean any fragment of single-stranded DNA whose sequence is complementary to a desired sequence: this fragment may, for example, be detected by hybridization with a labeled probe (for example by incorporation of radioactive atoms or fluorescent groups), which plays the role of a molecular "hook”.
  • the support of said device is selected from a glass membrane, a metal membrane, a polymer membrane, a silica membrane.
  • Such devices are, for example, DNA chips comprising one or more nucleotide sequences identified under the numbers SEQ ID No: 1 to SEQ ID No: 34 in the attached sequence listing.
  • the invention also relates to a kit intended for measuring the differential display of genes involved in angiogenic disorders comprising a device as previously described, specific primers and the accessories necessary for the amplification of the sequences extracted from a sample, their hybridization with the probes of the device and the performing the differential display measurements.
  • the invention also relates to a kit for the measurement of the differential display of genes involved in angiogenic disorders comprising a genetically modified cell line stably expressing the vector expressing at least one of the nucleotide sequences identified under the numbers SEQ. ID No: 1 to SEQ ID No: 34 in the attached sequence listing, or one of their fragments as a reference cell population and the means necessary for measuring said differential display.
  • the invention also relates to a kit for measuring the differential display of genes involved in angiogenic disorders comprising a genetically modified cell line stably expressing the vector expressing at least one antisense sequence of one of the nucleotide sequences. identified as SEQ ID No: 1 to SEQ ID No: 34 in the attached sequence listing, or a fragment thereof, as the reference cell population and the means necessary for measuring said differential display.
  • Figure 1 shows that the expression of GS-V1, GS-V2, GS-V3 and GS-V5 in human endothelial cells inhibit capillary tube formation and expression of GS-V4 in human endothelial cells stimulates formation of capillary tubes: IA-transfected endothelial cells) GS-V1 encoding the antisense transcript specific for GS-N1; IB) GS-V2 encoding the specific antisense transcript of GS-N2; IC) GS-V3 encoding the GS-N3 specific antisense transcript; ID) GS-V4 encoding the specific antisense transcript of GS-N4 and its counterpart GS-N5; IE) GS-V5 encoding the GS-N6 specific antisense transcript and its GS-N7 counterpart, and the GS-N8 specific antisense transcript and its GS-N9, GS-N10 and GS-NII counterparts; IF) the empty vector (Control).
  • Figure 2 shows that the expression of GS-V6 / GS-V7, GS-V8, GS-V9 and GS-V10 in human endothelial cells inhibits the formation of capillary tubes: endothelial cells transfected with 2A) GS-V6 coding for the specific antisense transcript of GS-N12; 2B) GS-V7 encoding the specific antisense transcript of GS-N13; 2C) GS-V8 encoding the specific antisense transcript of GS-N14; 2D) GS-V9 encoding the specific antisense transcript of GS-N15; 2E) GS-VlO encoding the antisense transcript specific for GS-16; 2F) the empty vector (Control).
  • Figure 3 shows that the expression of GS-VI1, GS-V12, GS-V13, GS-V14, GS-V15, in human endothelial cells inhibits the formation of capillary tubes: endothelial cells transfected with 3A) GS-VII encoding the specific antisense transcript of GS-N17; 3B) GS-V12 encoding the antisense transcript specific for GS-N18 and its counterpart GS-N19; 3C) GS-V13 encoding the antisense transcript specific for GS-N20; 3D) GS-V14 coding for the antisense transcript specific for GS-N21; 3E) GS-V15 encoding the specific antisense transcript of GS-N22; 3F) the empty vector (Control).
  • Figure 4 shows that the expression of GS-V16, GS-V17, GS-V18, GS-V19, GS-V20 in human endothelial cells inhibits the formation of capillary tubes: endothelial cells transfected with 4A) GS-V16 coding for the antisense transcript specific for GS-N23; 4B) GS-V17 encoding the specific antisense transcript of GS-N24; 4C) GS-V18 encoding the GS-N25 specific antisense transcript; 4D) GS-V19 encoding the specific antisense transcript of GS-N26 and its counterparts GS-N27 and GS-N28; 4E) GS-V20 encoding the specific antisense transcript of GS-N29 and 4F) the empty vector (Control).
  • Figure 5 shows that the expression of GS-V21, GS-V22,
  • GS-V23 in human endothelial cells inhibits capillary tube formation: endothelial cells transfected with 5A) GS-V21 encoding GS-N30 specific antisense transcript; 5B) GS-V22 coding for the antisense transcript specific for GS-N31, and its counterparts
  • Umbilical vein endothelial cells under said four culture conditions are then used to identify the genes encoding the cellular constituents involved in the regulation of angiogenesis.
  • the endothelial cells are maintained in complete medium (EGM-2 from Clonetics).
  • FGF2 at concentrations of between 5 ng / ml and 60 ng / ml, preferably between 10 and 40 ng / ml
  • VEGF at concentrations of between 10 ng / ml and 60 ng / ml, preferably between 30 ng / ml and 50 ng / ml
  • PF4 at concentrations between 0, 1 and 5 ⁇ g / ml, preferably between 0.5 ⁇ g / ml and 1 ⁇ g / ml
  • TNF- ⁇ at concentrations of between 20 ng / ml and 100 ng / ml, preferably between 30 ng / ml and 60 ng / ml
  • IFN- ⁇ at concentrations of between 50 ng / ml and 200 ng / ml, preferably between 80 ng / ml and 120 ng / ml
  • Ang-2 at concentrations of between 20 ng / ml and 800 ng /
  • VEGF vascular endothelial growth factor.
  • FGF2 Basic growth factor of the fibroblast.
  • PF4 Platelet factor 4.
  • TNF- ⁇ tumor necrosis factor alpha
  • TNF- ⁇ tumor necrosis factor alpha
  • TNF- ⁇ tumor necrosis factor alpha
  • TNF- ⁇ tumor necrosis factor alpha
  • the gene expressions can then be compared using DNA chips, SAGE, a quantitative PCR amplification reaction, viral vectors to construct subtractive libraries, or differential display analysis.
  • HUVEC grown on a collagen gel in the presence of the various factors used, according to the RNeasy Mini kit method (Qiagen) by integrating a DNase I digestion step according to the protocol recommended by the manufacturer.
  • the differential display from the total RNAs is carried out according to the method described by Liang and Pardee (1992, Science, 14; 257 (5072): 967-7) using the ⁇ P 33 -ATP in isotopic dilution in the course of time. PCR amplification for band visualization by autoradiography of electrophoresis gels.
  • DNA fragments differentially present on the gel as a function of the culture conditions analyzed are cut out, reamplified, cloned in a PGEM plasmid. easy vector, Promega), sequences and identified by questioning the BLAST bank.
  • each identified sequence is tested on the model of in vitro angiogenesis with human endothelial cells transfected with an expression vector comprising an antisense oligonucleotide of said sequence.
  • the amplification of the cloned fragment in the bacterial plasmid is carried out by means of particular primers, selected from GS-PGS-F, GS-PGM-R or GS-PGM-F and GS-PG sequences.
  • PGS-R hybridizing to the regions of the plasmid flanking the cloned gene and also comprising in their ends the restriction sites (SalI and MIuI sites), not contained in the cloned fragment, and present in the multisite region of the expression vector.
  • restriction sites can be interchanged depending on whether the fragment has been cloned into the bacterial plasmid in its sense or antisense orientation.
  • primers contain at each of their ends a site of a different restriction enzyme (SalI: GTCGAC or MIuI: ACGCGT).
  • Amplified fragments of each gene are obtained by PCR from the bacterial plasmids containing the identified gene fragment using said primers. These fragments are purified, digested with SalI and MIuI restriction enzymes and inserted into an expression vector in mammals of the pCi-neo vector type (Promega), itself digested with these two restriction enzymes. Each fragment is introduced in the antisense orientation.
  • the vectors that can be used to demonstrate the functionality of the genes identified in the present invention in the mechanism of angiogenesis include any mammalian expression vector system comprising a promoter which allows the expression of a cloned gene, by way of example, mention may be made of the "strong" promoter of human cytomegalovirus (CMV).
  • CMV cytomegalovirus
  • Other constitutive or inducible expression vectors that may also be used are indicated in the non-exhaustive list below:
  • Vectors marketed by the Promega Company vectors with a "strong" promoter for a high level mammalian cells
  • pCI Mammalian expression vector expression expression expression expression vector cloning vector pALTER (R) * -MAX vectors marketed by Invitrogen: (pcDNA3.1, / hygro, - / Zeo , pcDNA4 / HisMAx, -E, base pairsCE4, pRcRSV, pRcCMV2, pSecTag2, - / hygro secretion vectors, vectors pEBVHis A, B and C), mammalian expression vectors marketed by Clontech (pIRES, pIRES-EYFP pIRES2-EGFP, pCMV-Myc and pCMV-HA), Epitope-tagged pTRE, VP16 Minimal Domain vectors (ptTA 2, ptTA 3 and ptTA 4), bidirectional Tet expression vectors (base
  • Each vector comprising said antisense fragment is then produced in E. CoIi, extracted, purified and quantified.
  • a jug of each vector is incubated in the presence of a transfecting agent (effectene, Qiagen) following the protocol recommended by the manufacturer with the endothelial cells. Twenty-four hours after transfection, the endothelial cells are trypsinized and plated on the extracellular matrix containing the angiogenic factors in this case the matrigel according to the model described by Grant et al. (1989, Cell, 58 (5): 933- 43). After 24h incubation, vessel formation is observed and compared to control cells transfected with the empty mammalian expression vector. 5. Establishment of the library of stable lines expressing the expression vectors containing the gene sequences or their fragments or the antisense sequences.
  • Expression systems may include a selection marker for an antibiotic (a gene of antibiotic resistance) to select transfected cells stably expressing the vector comprising the nucleic acid cloned in said vector and, either in the same vector or in a vector cotransfected 2nd.
  • a selection marker for an antibiotic a gene of antibiotic resistance
  • This expression vector may be a constitutive or inducible expression system.
  • the stable lines for the expression of the antisense oligonucleotide corresponding to each identified gene were obtained with a constitutive expression vector and after selection in the presence of antibiotic.
  • the BAEC endothelial cells are trypsinized and seeded at a rate of 80,000 cells / well in six-well plate in the presence of 700 ⁇ g / ml of antibiotic G418. (Promega) A control well is inoculated with untransfected cells.
  • the medium is changed every three days with a refill of the antibiotic.
  • the control cells are removed after 8 to 10 days, the antibiotic resistant cells are harvested at confluence (after 2 to 3 weeks) and then transferred into culture flasks always in the presence of the antibiotic. Stable lines are then tested for their ability to form or not form vessels in the in vitro angiogenesis assay.
  • nucleic acid sequences identified in the sequence listing provided in the appendix by the numbers SEQ ID No. 1, 2, 4, 5, 9 to 11, 13, 17 to 19, 27 to 29 and 34 and the proteins identified in the sequence listing provided by SEQ ID Nos. 35, 37, 38, 43, 47 to 49 and 57 have not previously been identified as having a biological role and still less as having a role in the process of angiogenesis or the differentiation of endothelial cells into capillary tubes. These proteins are described below.
  • the differential display method described above allowed the identification of the following mRNAs:
  • GS-N1 mRNA of 1041 base pairs, identified by the sequence SEQ ID No: 1 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under accession number BC002759.
  • the sequence of this mRNA has a coding sequence from nucleotide 213 to nucleotide 482.
  • a protein, GS-P1 resulting from the translation of this mRNA (SEQ ID No. 35 in the attached sequence listing) has been identified. This protein is composed of 89 amino acids.
  • GS-N2 4275 base pair mRNA identified by the sequence SEQ ID No: 2 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under accession number BC040192.
  • GS-N3 6104 bp mRNA identified by the sequence SEQ ID No: 3 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under accession number XM_497078.
  • nucleoporin 188 The sequence of this mRNA has a coding sequence of nucleotide 438 to nucleotide 5687.
  • Nucleoporine 188kDa is part of the family of about thirty proteins called nucleoporins which constitute on the nuclear double membrane large protein structures forming nuclear pores and serving as sites of translocation of macromolecules between the nucleus and cytoplasm. Studies have shown that a nucleoporin has a unique role in the regulation of nuclear pore function and the transport of proteins and RNAs.
  • NUP88 nucleoporin has been associated with high aggression in breast cancer (Agudo et al, Int J Cancer, 2004 May 1, 109 (5): 717-20).
  • NUP98 nucleoporin 98kDa
  • GS-N4 mRNA of 1768 bp, identified by the sequence SEQ ID No: 4 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under accession number BC002509.
  • GS-N4 The sequence of this mRNA (GS-N4) has a coding sequence from nucleotide 176 to nucleotide 1387.
  • a protein, GS-P3, (SEQ ID No. 37 in the attached sequence listing) resulting from the translation of this mRNA has been identified. This protein is composed of 403 amino acids.
  • This sequence is homologous to the GS-N5 sequence.
  • GS-N5 1552 base pair mRNA identified by the sequence SEQ ID No: 5 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under accession number BC008630.
  • GS-N5 The sequence of this mRNA (GS-N5) has a partial coding sequence from nucleotide 1 to nucleotide 949.
  • This new 44kDa protein contains a PHD Zinc finger domain, a motif mainly found in proteins involved in transcriptional regulation in eukaryotes (reviewed Trends Biochem Sci., 1995 Feb; 20 (2): 56-9).
  • GS-N6 3181 base pair mRNA identified by the sequence SEQ ID No: 6 in the attached sequence listing.
  • GS-N6 The sequence of this mRNA (GS-N6) has a coding sequence of nucleotide 213 to nucleotide 2207.
  • This sequence is homologous to the GS-N7 sequence.
  • GS-N7 2404 base pair mRNA identified by the sequence SEQ ID No: 7 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under accession number X03444.
  • the sequence of this mRNA (GS-N7), has a coding sequence of nucleotide 211 to nucleotide 2319.
  • the LMNA gene codes for a protein called lamin A / C isoform 1.
  • the lamins are the main components of the nuclear lamina. These proteins are important in a variety of cellular functions such as nuclear assembly, replication, transcription, and nuclear integrity (reviewed: Curr Opin Cell Biol 2002 Jun, 14 (3): 357-64).
  • GS-N8 mRNA of 2570 base pairs identified by the sequence SEQ ID No: 8 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under the accession number AB005047.
  • GS-N8 The sequence of this mRNA (GS-N8) has a coding sequence from nucleotide 64 to nucleotide 1341.
  • the SAB protein is an SH3 domain binding protein, its role in the signaling voice of Bruton tyrosine kinase (Btk) has been suggested by the demonstration of its binding with the SH3 domain of this kinase (Biochem Biophys Res Commun 1998 Apr 17; 245 (2): 337-43). Its role in the signaling voice of the c-Jun protein N-terminal kinase has also been suggested (Biochem J. 2002 Nov 1; 367 (Pt 3): 577-85).
  • Btk Bruton tyrosine kinase
  • c-Jun N-terminal kinase has been shown to be involved in angiogenesis (Jimenez et al, Oncogene, 2001 Jun 7; 20 (26): 3443-8) and more recently, augmented expression of Btk was observed during in vivo angiogenesis (2004, Zippo et al, Blood).
  • This sequence has sequence homology with GS-N9, GS-N10, GS-NII sequences less than 90%. However these four sequences exhibit a conserved sequence which I 1 antisense, identified in the sequence listing provided in the annex under the number SEQ ID NO: 67, allows the inhibition of the expression.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under the accession number AK090524.
  • GS-N10 mRNA of 5593 base pairs identified by the sequence SEQ ID No: 10 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under accession number AL133111
  • GS-NI1 2774 base pair mRNA identified by the sequence SEQ ID No: 11 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under accession number BX641159.
  • GS-N12 8974 base pair mRNA identified by the sequence SEQ ID No: 12 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under the accession number NM_015382
  • GS-N12 The sequence of this mRNA (GS-N12) has a coding sequence of nucleotide 324 to nucleotide 8162.
  • the HECTD1 protein is stored by its conserved domain in the HECT family of proteins that function as E3 ubiquitin ligase proteins, targeting specific proteins for ubiquitin-mediated proteolysis (Callaghan et al., Oncogene, 1998 Dec 31; 17 (26)). ): 3479-91).
  • the Smurfl protein another member of this family, plays a specific role in osteoblast cell differentiation and bone formation in vivo by inhibiting this differentiation (Zhao et al., J. Biol Chem. 26; 279 (13): 12854-9).
  • the Nedd4 protein also a member of the HECT family, has been described as regulating the stability and therefore the activity of the growth factor receptor IGF-I (Molecular Insulin-like Growth Factor I) (Mol CeIl Biol 2003 May; 9): 3363-72
  • IGF-I Molecular Insulin-like Growth Factor I
  • HECTD1 The specific role of HECTD1 is not yet described in the literature, and in particular no role has been described in the regulation of angiogenesis for this protein - GS-N13: 5346 base pairs identified under sequence number SEQ ID No. 13 in the attached sequence listing
  • a BLAST search in the GENBANK sequence database identifies it as accession number XM_291344. This mRNA has a coding sequence from nucleotide 1 to nucleotide 3522.
  • a protein, GS-P9, (SEQ ID No. 43 in the attached sequence listing), resulting from the translation of this mRNA has therefore been identified.
  • This protein is composed of 1173 amino acids.
  • protein still e unknown is characterized by a catalytic tyrosine kinase domain.
  • GS-N14 mRNA of 3769 base pairs identified under sequence number SEQ ID No. 14 in the attached sequence listing.
  • a BLAST search in the database sequences GENBANK allows to identify it under accession number NM__181847.
  • This mRNA has a coding sequence of the nucleotide
  • This protein is composed of 522 amino acids and is called AMIG02.
  • the Amigo 2 protein was recently discovered and has been classified into a new gene family encoding type I transmembrane proteins that contain a secretion signal sequence and a transmembrane domain
  • the Amigo 2 protein is still poorly known, it has never been described as implicated in angiogenesis.
  • GS-N15 mRNA of 7407 base pairs identified under the number SEQ ID No. 15 in the attached sequence listing.
  • a BLAST search in the GENBANK sequence database makes it possible to identify it under accession number NM_005650 s
  • This mRNA has a coding region of nucleotide 135 to nucleotide 6017. It has therefore been identified a protein, GS-PlI, (SEQ ID No. 45 in the attached sequence listing), resulting from the translation of this mRNA. This protein is composed of 1960 amino acids, and is called transcription factor 20, isoform 1 (TCF20).
  • This protein also known as SPBP, was originally described as a transcription factor that controls the expression of stromolysin, a metalloproteinase involved in tumor invasion and metastasis (Sanz et al., Cell Biol. 15 (6), 3164-3170 (1995). More recently, it has been reported that this protein Although nuclear contains several functional domains and stimulates the transcriptional activity of various transcription factors such as Ets1 or C-Jun, it is suggested to be a transcriptional coactivator (Rekdal et al., J Biol Chenu 2000 Dec 22; 275 (51)). : 40288-300).
  • GS-N16 2104 base pair mRNA identified under the number SEQ ID No. 16 in the attached sequence listing.
  • a BLAST search in the GENBANK sequence database makes it possible to identify it under the accession number NM_016408.
  • This mRNA has a coding sequence from nucleotide 125 to nucleotide 1888.
  • a GS-P12 protein (SEQ ID No. 46 in the attached list of sequences) has been identified, resulting from the translation of this mRNA.
  • This protein is composed of 587 amino acids, and is called protein 1 associated with the CDK5 regulatory subunit (CDK5RAP1).
  • This protein also called C42, or HSPC167, has been isolated and shown to associate with an activating subunit (p25nck5a derived from p35 nck5a ) of a cell cycle-associated protein kinase called cyclin-dependent protein kinase, CDK5 (Ching et al. Wang, Gene, 2000 Jan 25, 242 (1-2): 285-94).
  • cdks regulate proliferation, differentiation, senescence, and apoptosis.
  • Neuronal CDK5 has been implicated in the regulation of differentiation and neuronal migration.
  • the activity of Cdk proteins is regulated by complex mechanisms including phosphorylation of proteins, association with specific inhibitors.
  • CDK5RAP1 has been demonstrated in the regulation of angiogenesis - GS-N17: 5859 base pair mRNA identified as SEQ ID No 17 in the attached sequence listing .
  • a BLAST search in the GENBANK sequence database makes it possible to identify it under the accession number AK074056.
  • This mRNA (GS-N17) has a partial coding sequence from nucleotide 45 to nucleotide 935.
  • a new protein, GS-P13, (SEQ ID No. 47 in the attached sequence listing) has thus been identified, resulting from the translation of this mRNA.
  • This protein is composed of 296 amino acids.
  • This unknown protein, of 33kDa contains BTB / POZ and Kelch domains, the BTB / POZ domain is a conserved domain of protein-protein interaction (Xu et al, Int JMed Med 2004 Jan; 13 (1): 193
  • the proteins containing these domains constitute a large family whose physiological functions are still poorly understood (Ohmachi et al, Genes Cells, 1999).
  • Jun; 4 (6): 325-37 A member of this family has already been described involved in a process such as directed cell migration in Drosophila (Development, 2001 Aug; 128 (15): 3001-15) .
  • GS-N18 1694 base pair mRNA identified under the number SEQ ID No. 33 in the attached sequence listing.
  • a BLAST search in the GENBANK sequence database allows identify it under accession number BC001792.
  • This mRNA (GS-N18), has a coding sequence of nucleotide 164 to nucleotide 448. It has thus been identified a protein, GS-P14, (SEQ ID No. 48 in the attached sequence listing), resulting from the translation. of this
  • MRNA This protein is composed of 94 amino acids.
  • This 10kDa protein has no particular domain but contains a signal sequence of secretion and a transmembrane helix. This sequence is homologous to the GS-N19 sequence.
  • GS-N19 2437 base pair mRNA identified by the sequence SEQ ID No: 19 in the attached sequence listing.
  • a BLAST search based on GENBANK sequences makes it possible to identify it under the accession number AF370373.
  • This mRNA (GS-N19) has a coding sequence of nucleotide 628 to nucleotide 1533.
  • a protein, GS-P15 (SEQ ID No. 49 in the attached sequence listing), resulting from the translation of this mRNA has thus been identified. .
  • This protein, isoform of the GS-P14 protein is composed of 301 amino acids.
  • This isoform is characterized by a domain called ubiquitin, a family of ubiquitins, molecules involved in the proteolysis of proteins that regulates the "turnover of proteins", in order to control the progression of the cell cycle.
  • GS-N20 a 1714 base pair mRNA identified under the number SEQ ID No. 20 in the attached sequence listing.
  • a BLAST search can identify it under accession number BC022870 in the GENBANK sequence database.
  • the sequence of this mRNA has a coding sequence from nucleotide 90 to nucleotide 1424. It was thus identified a GS-P16 protein resulting from the translation of this mRNA. This protein is composed of 444 amino acids. It is identified as SEQ ID No. 50 in the attached sequence listing, called interferon-induced protein 44 (IFI44).
  • IFI44 interferon-induced protein 44
  • the gene encoding a novel antigen protein, p44 was originally isolated from chimpanzees infected with hepatitis virus (Takahashi et al., 1990, J Gen Virol., 71 (Pt 9): 2005-ll). . Subsequently, it has been identified in humans as inducible by interferon (Kitamura et al, Eur J Biochem 1994 Sep 15; 224 (3): 877-83). To date, this protein has not been described as being involved in angiogenesis.
  • GS-N21 1715 base pair mRNA identified under the number SEQ ID No. 21 in the attached sequence listing.
  • a BLAST search can identify it under the accession number NM_004905 in the GENBANK sequence database.
  • This mRNA, GS-N21 has a coding sequence of nucleotide 52 to nucleotide 726. It has thus been identified a protein, GS-Pl7, (SEQ ID No. 51 in the attached sequence listing), resulting from the translation of this MRNA, composed of 224 amino acids, called peroxiredoxin 6 (PRDX6).
  • PRDX6 peroxiredoxin 6
  • Peroxiredoxin 6 protein (also known as antioxidant protein 2, non-selenium glutathione peroxidase, acidic calcium-independent phospholipase A2, 1-Cys peroxiredoxin) belongs to the growing and ubiquitous family of peroxiredoxins which are multifunctional enzymes with peroxidase in vitro, and In vivo are involved in many cellular processes known to be responsive to reactive oxygen such as pathophysiological processes including oxygen adaptation, atherosclerosis, cancer, cell differentiation (WAGNER et al, Biochem J. (2002)). 366): 777-785.
  • PRDX6 is a unique non-redundant antioxidant that works independently of other peroxiredoxins and antioxidant proteins.
  • PRDX6 Very abundant in epithelial cells, PRDX6 was found in the cytosol (Wang et al., J. Biol Chem., Vol 278, Issue 27, 25179-25190, JuIy 4, 2003). It has also been found in endothelial cells only in the cytosol (Stuhlmeier et al, Eur J Biochem, 2003 Jan; 270 (2): 334-41).
  • this protein has not been described as having a role in the regulation of angiogenesis.
  • GS-N22 5978 base pair mRNA identified under the number SEQ ID No. 22 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under the accession number AF220037 in the GENBANK sequence database.
  • This mRNA has a coding sequence from nucleotide 1801 to nucleotide 3933.
  • a protein, GS-P18 SEQ ID No. 52 in the attached list of sequences
  • TRIM9 tripartite isoform beta motif protein
  • the TRIM9 protein belongs to a family characterized by a conserved domain, the tripartite motif (TRIM).
  • the TRIM is composed of three zing binding domain, a RING (R), a B-box type 1 (B1) and a B-box type 2 (B2) followed by a coiled-coil region.
  • R RING
  • B1 B-box type 1
  • B2 B-box type 2
  • TRIM9 protein also contains a fibronectin type III domain, a modulus present in both extracellular and intracellular proteins.
  • Genes of the TRIM family have been involved in processes various, such as cell growth and growth and oncogenesis and other pathologies (EMBO J. 2001 May 1; 20 (9): 2140-51; Berti et al., Mech Dev. 2002 May; 113 (2): 159 -62.) • TRIMII, for example, would play a role in regulating the level of intracellular expression of a neuroprotective peptide that specifically suppresses neurotoxicity related to Alzheimer's disease through the protein-controlled pathway of protein degradation.
  • TRIM9 ubiquitins
  • GS-N23 5858 bp mRNA identified as SEQ ID No. 23 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under the accession number AF213987 in the GENBANK sequence database.
  • This mRNA has a coding sequence from nucleotide 66 to nucleotide 2213.
  • a protein, GS-P19 (SEQ ID No. 53 in the attached list of sequences), resulting from the translation of this mRNA, has been identified.
  • This protein is composed of 715 amino acids and is called MCEF protein.
  • the MCEF protein has been described as a new member of the family of AF4 transcription factors involved in lymphoblastic leukaemias Estable et al., J Biomed Sci. 2002 May-Jun; 9 (3) -.234-45).
  • the MCEF protein is still very little studied and to date, no role in the regulation of angiogenesis has been described for this protein.
  • GS-N24 3907 base pair mRNA identified under the number SEQ ID No. 24 in the attached sequence listing.
  • a search BLAST makes it possible to identify it under the number accession number NM_012318 in the GENBANK sequence database.
  • This mRNA has a coding sequence of nucleotide 298 to nucleotide 2517.
  • the LETM1 protein contains two "EF-Hand" domains, a transmembrane domain, a leucine Zipper domain and several coiled-coil domains. Based on its possible calcium binding property and its involvement in the calcium signaling pathway, this protein has been suggested to be implicated in a mental illness, Wolf-Hirschhorn syndrome, this protein being deleted in many patients with this syndrome (Endele et al., Genomics, 1999 Sep 1; 60 (2): 218-25. A recent study has shown a mitochondrial localization of this protein (Schlickum et al, Genomics, 2004 Feb; 83 (2)). : 254-61).
  • GS-N25 a mRNA of 7190 base pairs identified under the number SEQ ID No. 41 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under the accession number NM_020119 in the GENBANK sequence database.
  • This mRNA has a coding sequence of nucleotide 389 to nucleotide 3097.
  • GS-P21 SEQ ID No. 55 in the attached list of sequences
  • ZAP protein is a CCCH type Zinc finger protein. His current role is in the prevention of retrovirus infection. The expression of this ZAP protein has been shown to cause a deep and specific loss of viral mRNAs in the cytoplasm of the cell without affecting nuclear mRNAs suggesting a role in the inhibition of viral replication of infected cells (Gao et al., Science 2002 Sep 6; 297 (5587): 1703-6 ). No other role is known at present and no role in the regulation of angiogenesis has been described so far for this protein.
  • GS-N26 2359 base pair mRNA identified as SEQ ID No. 26 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under the accession number NM_022777 in the GENBANK sequence database.
  • This mRNA, GS-N26 has a coding sequence of nucleotide 41 to nucleotide 598. It has thus been identified a protein, GS-P22, (SEQ ID No. 56 in the attached sequence listing), resulting from the translation of this mRNA. This protein is composed of 185 amino acids and is called RABL5 protein.
  • the gene encoding the RABL5 protein has recently been described (Ota et al., Nat Genet 36 (1), 40-45 (2004) and the protein has been classified by its conserved domains as a member of the Rab GTPAse family. belonging to the superfamily of GTP-binding Ras proteins, which have emerged as cell-membrane regulators, particularly formation, vesicular transport, and membrane fusion (reviews: Prekeris R, Scientific World Journal, 2003 Sep 15; 3: 870-80, Stenmark H and Olkkonen VM., Genome Biol 2001; 2 (5)). This superfamily comprises over 80 highly conserved proteins that are involved in multiple voices of intracellular signaling and function as switches.
  • RABL5 protein is still poorly known and its exact role has not yet been discovered, no role in angiogenesis has been described to date.
  • GS-N26 has a sequence homology with the GS-N27 and GS-N28 sequences of less than 90%. However, these three sequences have a conserved sequence which I 1 antisense, identified in the sequence listing provided in the annex under the number SEQ ID NO: 81, allows the inhibition of the expression.
  • - GS-N27 1782 base pair mRNA, identified under the number SEQ ID No. 27 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under accession number BC050531 in the GENBANK sequence database.
  • GS-N28 mRNA of 2587 base pairs, identified under the number SEQ ID No. 28 in the attached sequence listing.
  • a BLAST search can identify it under the accession number AL157469 in the GENBANK sequence database.
  • GS-N29 2520 bp mRNA identified under the number SEQ ID No. 29 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under the accession number XM_211534 in the GENBANK sequence database.
  • This mRNA (GS-N29) has a coding sequence of nucleotide 484 to nucleotide 792. It has thus been identified a protein, GS-P23, (SEQ ID No. 57 in the attached sequence listing), resulting from the translation of this mRNA.
  • This protein is composed of 102 amino acids.
  • This new 11 kDa protein (102 amino acids) has no particular domain, is extracellular and has a secretory sequence of secretion.
  • GS-N30 mRNA of 7300 base pairs identified under the number SEQ ID No. 30 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under accession number NM__003023 in the GENBANK sequence database.
  • This mRNA (GS-N30), has a coding sequence of nucleotide 262 to nucleotide 1947. It has thus been identified a protein, GS-P24 (SEQ ID No. 58 in the attached sequence listing), resulting from the translation of this mRNA. This protein is composed of 561 amino acids and is called SH3 domain binding protein 2 (SH3BP2).
  • SH3BP2 SH3 domain binding protein 2
  • This protein has been identified in bladder cancer and by its structure it has been suggested to play a role in signaling and could be a negative regulator of the abl oncogene (Bell et al, Genomics, 1997 Sep 1; (2): 163-70 Recently, this protein has been described as an adapter protein in signaling pathways by promoting the transcriptional activity of two NFAT / AP-1 transcription factors (known to be involved in gene transcription). interleukin 2) in T cells through activation of Ras - and calcineurin - dependent pathways (Foucault et al., J Biol Chem 2003 Feb 28, 278 (9): 7146-53).
  • GS-N31 1701 base pair mRNA identified under the number SEQ ID No. 31 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under the accession number AF380162 in the GENBANK sequence database.
  • This mRNA (GS-N31) has a coding sequence from nucleotide 19 to nucleotide 1542.
  • a protein, GS-P25 (SEQ ID No. 59 in the attached sequence listing), resulting from the translation of this
  • MRNA This protein is composed of 507 amino acids and is called FAPP2 protein.
  • GS-N31 This mRNA sequence (GS-N31) is homologous to GS-N32 and GS-N33 sequences.
  • GS-N32 2836 base pair mRNA identified under the number SEQ ID No. 32 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under the accession number AK023180 in the GENBANK sequence database.
  • This mRNA has a coding sequence of nucleotide 323 to nucleotide 1441.
  • a protein, GS-P26 SEQ ID No. 60 in the attached sequence listing
  • amino acids and called Protein similar to FAPP2 protein The gene coding for the protein FAPP2 was identified in 2002 by Strausberg (Proc Natl Acad Sci U.S.A 99 (26), 16899-16903), it is highly similar, moreover, to a protein NY-BR-86 described as a breast cancer antigen (Scanlan et al., 2001, Cancer Immun.1,4).
  • This protein has a conserved glycolipid transfer domain and a pleckstrin homology domain.
  • This domain is shared by a group of novel proteins that have binding specificities with the phosphorylated derivatives of inositol. These Proteins are described as potentially adapter proteins because they do not have catalytic domains. These molecules may be key mediators of cellular responses that are specifically regulated by the second messenger (the phosphorylated derivative of inositol) (Dowler et al., Biochem J. (2000) 351, 19-31).
  • FAPP2 The exact role of FAPP2 is not yet known, its role in angiogenesis has not yet been described.
  • This mRNA sequence (GS-N32) is homologous to GS-N31 and GS-N33 sequences.
  • GS-N33 mRNA of 2004 base pairs identified under the number SEQ ID No. 33 in the attached sequence listing.
  • a BLAST search can identify it under accession number BC002838 in the GENBANK sequence database.
  • This mRNA has a coding sequence from nucleotide 92 to nucleotide 1414.
  • a protein, GS-P27 (SEQ ID No. 61 in the attached sequence listing), resulting from the translation of this mRNA, composed of 440 acids, has been identified. amino is called Protein linked to the proliferation potential.
  • This mRNA sequence (GS-N33) is homologous to GS-N31 and GS-N32 sequences.
  • GS-N34 1789 base pair mRNA identified under the number SEQ ID No. 34 in the attached sequence listing.
  • a BLAST search makes it possible to identify it under the accession number AK057491 in the GENBANK sequence database.
  • an antisense oligonucleotide specific for each of the identified genes chosen from the oligonucleotides identified by the sequences SEQ ID No. 62 to SEQ ID. : 86 in the attached sequence listing was introduced into the vector pCI-neo expression vector in antisense orientation.
  • GS-V1 to GS-V23 identified by their sequence SEQ ID No: 87 to SEQ ID No: 109 in the attached sequence listing were used to repress expression of the gene encoding this mRNA in cells. endothelial cells following transfection of the latter by this vector.
  • Human endothelial cells were then stimulated by angiogenic factors.
  • SEQ ID N. 1 to SEQ ID No. 3 inhibits the formation of neovessels by endothelial cells;

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP06709059A 2005-01-10 2006-01-10 An der angiogeneseregulierung beteiligte gene, pharmazeutische zubereitungen damit und deren verwendung Withdrawn EP1836304A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0500217A FR2880631A1 (fr) 2005-01-10 2005-01-10 Genes impliques dans la regularisation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications
PCT/FR2006/000048 WO2006075084A2 (fr) 2005-01-10 2006-01-10 Genes impliques dans la regulation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications

Publications (1)

Publication Number Publication Date
EP1836304A2 true EP1836304A2 (de) 2007-09-26

Family

ID=34954624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06709059A Withdrawn EP1836304A2 (de) 2005-01-10 2006-01-10 An der angiogeneseregulierung beteiligte gene, pharmazeutische zubereitungen damit und deren verwendung

Country Status (5)

Country Link
US (1) US20100135985A1 (de)
EP (1) EP1836304A2 (de)
CA (1) CA2593464A1 (de)
FR (1) FR2880631A1 (de)
WO (1) WO2006075084A2 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
WO2001009318A1 (fr) * 1999-07-29 2001-02-08 Helix Research Institute Genes associes au cancer du foie
FR2798674B1 (fr) * 1999-09-21 2004-01-30 Mahmood Salman Al Procede d'identification de nouveaux genes impliques dans la regulation de l'angiogenese, etude de ces genes et leur utilisation a des fins therapeutiques
JP2003511012A (ja) * 1999-09-24 2003-03-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３２個のヒト分泌タンパク質
FR2836687A1 (fr) * 2002-03-04 2003-09-05 Gene Signal Genes impliques dans la regulation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications
WO2005074560A2 (en) * 2004-02-02 2005-08-18 The General Hospital Corporation Compositions and methods that enhance rna interference

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006075084A2 *

Also Published As

Publication number Publication date
CA2593464A1 (fr) 2006-07-20
US20100135985A1 (en) 2010-06-03
FR2880631A1 (fr) 2006-07-14
WO2006075084A3 (fr) 2006-10-05
WO2006075084A2 (fr) 2006-07-20

Similar Documents

Publication Publication Date Title
FR2823220A1 (fr) Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
EP2161280A2 (de) An der Regulierung der Angiogenese beteiligte Gene, solche Gene enthaltende pharmazeutische Zubereitungen und ihre Anwendungen
EP1814579B1 (de) Mutiertes netrin-4, fragmente davon und ihre verwendung als medikamente
WO2011054644A1 (en) A low density lipoprotein-related protein 1 splice variant as cancer marker
EP1648494B1 (de) Anti-angiogenetisches Mittel und seine Verwendung bei der Krebsbehandlung
WO2019195717A1 (en) Compositions and methods of treatment of vision loss through generation of rod photoreceptors from müller glial cells
EP1214452B1 (de) Verfahren zur identifizierung neuartiger gene, die bei der regulation der angiogenese einer rolle spielen, analyse dieser gene sowie ihre verwendung zu therapeutischen zwecken
EP2516676B1 (de) Mitf als marker für krebsprädisposition
EP1836304A2 (de) An der angiogeneseregulierung beteiligte gene, pharmazeutische zubereitungen damit und deren verwendung
EP1483289B1 (de) Gene die angiogenese regulieren, pharmazeutische zusammensetzungen die sie enthalten und deren verwendungen
FR2821625A1 (fr) Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
WO2010018764A1 (ja) 血管新生制御剤，及びそのスクリーニング方法，並びにスクリーニング用キット
Huang et al. TSP2 Deficiency Promotes Fibroblast Proliferation and Migration With Enhanced WNT4/β‐Catenin/TGFb3
FR2836686A1 (fr) Genes impliques dans la regulation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications
WO2001055172A2 (fr) COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFR$g(a)
JP2006288243A (ja) シスプラチン耐性細胞株，その製造方法，シスプラチン感受性増強剤のスクリーニング方法，医薬組成物，及びスクリーニング用試薬
FR2878165A1 (fr) Nouvelles utilisations des netrines
FR2843753A1 (fr) Genes impliques dans la regulation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications
Segura Puimedon Use of mouse models to establish genotype-phenotype correlations in Williams-Beuren syndrome
Han et al. Increased Myosin Light Chain Kinase Expression in Hypertension: Regulation by SRF via an Insertion Mutation in the Promoter
CA2399939A1 (fr) Partenaires du domaine ptb1 de fe65, preparation et utilisations
JPWO2001010905A1 (ja) 血管平滑筋細胞の異常増殖を抑制するための医薬組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070619

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090112

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENE SIGNAL INTERNATIONAL SA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110218